Ethiopia has taken an historic step to become the second country in the world to approve an old drug, misoprostol, for a new use, controlling postpartum hemorrhage. Postpartum hemorrhage, life-threatening bleeding following childbirth, is the leading cause of maternal deaths worldwide.
Our non-profit organization, Venture Strategies for Health and Development, worked with UC Berkeley's School of Public Health to help the Ethiopian Ministry of Health obtain this regulatory approval. Now the drug will be imported and made available for saving the lives of the approximately 8,200 Ethiopian women who die each year from this condition.
Our team helped Nigeria become the first country to obtain a similar regulatory approval in January.
Venture Strategies for Health and Development and UC Berkeley will continue to assist the Ethiopian Ministry of Health develop their rollout of misoprostol throughout the country with specific focus on distribution to rural areas.
Our nonprofit organization works to improve the health of low income people in resource-poor settings, by making use of existing market forces around the world. We are providing policy, medical, and distribution strategy support to several countries evaluating the introduction of misoprostol to save mothers' lives. By facilitating South-South trade, we help countries obtain high-quality low-cost health products from generic manufacturers, at their request.
If you would like to read more about our misoprostol projects and related publications, we invite you to see our web site.